Insider Selling: Aclaris Therapeutics Inc (NASDAQ:ACRS) Major Shareholder Sells 339,537 Shares of Stock

Aclaris Therapeutics Inc (NASDAQ:ACRS) major shareholder James E. Flynn sold 339,537 shares of the stock in a transaction that occurred on Friday, June 21st. The stock was sold at an average price of $4.62, for a total transaction of $1,568,660.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

ACRS stock traded down $0.01 during midday trading on Thursday, hitting $2.10. The company’s stock had a trading volume of 280,876 shares, compared to its average volume of 607,114. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.33 and a quick ratio of 4.30. The company has a market capitalization of $86.25 million, a price-to-earnings ratio of -0.52 and a beta of 0.77. Aclaris Therapeutics Inc has a 12 month low of $1.93 and a 12 month high of $20.75. The business has a 50 day moving average price of $3.69.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.91) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.05). The firm had revenue of $5.04 million for the quarter, compared to the consensus estimate of $5.13 million. Aclaris Therapeutics had a negative net margin of 999.53% and a negative return on equity of 78.05%. On average, analysts expect that Aclaris Therapeutics Inc will post -2.87 EPS for the current year.

Several research analysts have weighed in on ACRS shares. Svb Leerink downgraded Aclaris Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday, June 27th. Zacks Investment Research upgraded Flagstar Bancorp from a “hold” rating to a “buy” rating and set a $38.00 price target for the company in a research note on Monday, July 8th. Cantor Fitzgerald restated an “overweight” rating and issued a $130.00 price target (up from $116.00) on shares of Zoetis in a research note on Wednesday, June 12th. Leerink Swann downgraded Aclaris Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday, June 27th. Finally, BidaskClub downgraded Zebra Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, May 8th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $19.69.

Several hedge funds and other institutional investors have recently bought and sold shares of ACRS. Citigroup Inc. boosted its position in shares of Aclaris Therapeutics by 3,200.0% during the 4th quarter. Citigroup Inc. now owns 3,993 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 3,872 shares during the last quarter. Great West Life Assurance Co. Can bought a new position in shares of Aclaris Therapeutics during the 4th quarter valued at approximately $43,000. BNP Paribas Arbitrage SA boosted its position in shares of Aclaris Therapeutics by 82,200.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 7,407 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 7,398 shares during the last quarter. Legal & General Group Plc boosted its position in shares of Aclaris Therapeutics by 64.1% during the 4th quarter. Legal & General Group Plc now owns 6,495 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 2,536 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in shares of Aclaris Therapeutics during the 1st quarter valued at approximately $70,000. Hedge funds and other institutional investors own 91.79% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream.

Featured Article: Price Target

Insider Buying and Selling by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.